Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. by De Caterina, R & John Camm, A
1 
 
 
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis:  
the concept for a trial 
 
Short title: NOACs in rheumatic atrial fibrillation 
 
Raffaele De Caterina1 and A. John Camm2 
 
1 Institute of Cardiology and Center of Excellence on Aging, G. d’Annunzio University – Chieti, and G. 
Monasterio Foundation – Pisa, Italy 
2 Division of Clinical Sciences, St George’s University of London, London, UK 
 
Total word count: 5246 
 
Correspondence: 
Raffaele De Caterina, MD, PhD 
Institute of Cardiology, G. d’Annunzio University - Chieti-Pescara 
C/o Ospedale SS. Annunziata 
Via dei Vestini, 31 
66013 Chieti 
Tel.: +39-0871-41512 
FAX: +39-0871-402817 
E-mail: rdecater@unich.it  
Manuscript (incl.refs, Acknowledgments, Funding, Ethics, etc follow guidelines)
Click here to download Manuscript (incl.refs, Acknowledgments, Funding, Ethics, etc follow guidelines): 3. Europace Text 2015-07-18-revised.doc 
2 
 
 
ABSTRACT 
 
Patients at thromboembolic risk with non-valvular AF can now be managed either with a vitamin K 
antagonist (VKA) or with a fixed-dose of a non-VKA oral anticoagulant (NOAC), whilst patients with 
valvular AF have been restricted to VKAs on the basis of a potentially higher risk and different mechanism 
of thrombosis, and the lack of sufficient data on the efficacy of NOACs. The terms “non-valvular AF” and 
“valvular AF” have not been however consistently defined. “Valvular” AF has included any valvular 
disorder, including valve replacement and repair. 
In AF with rheumatic mitral disease, observational studies strongly suggest that VKA treatment is valuable. 
These patients have not been included in NOAC trials, but there is also no stringent argument to have 
excluded them. This is at sharp variance from patients with mechanical valves, also excluded from the 
pivotal phase III trial comparing warfarin with NOACs, but in whom a single phase-II trial of dabigatran 
etexilate against VKA treatment was stopped prematurely because of increased rates of thromboembolism as 
well as increased bleeding associated with dabigatran. Until more data are available, such patients should be 
therefore managed with VKAs.  
We here propose an open-label randomized trial of one of the NOACs against the best-of-treatment available 
in regions of the world in which rheumatic heart disease is still highly prevalent, aiming at showing the 
superiority of the NOAC used against current standard treatment. 
 
 
Key words: valvular atrial fibrillation; valvular heart disease; rheumatic heart disease; thromboembolism; 
vitamin K antagonists; oral anticoagulants; non-vitamin K antagonist oral anticoagulants; NOACs; mitral 
stenosis; prosthetic valve; artificial valve; bioprosthetic valve; mechanical valve; stroke. 
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INTRODUCTION 
 
Despite the same electrophysiologic abnormality, the risk of stroke and systemic embolism in atrial 
fibrillation (AF) ranges from <1%/year to >20%/year and can be assessed by simple clinical risk factors 1. 
This has led to the gradual adoption of vitamin K antagonist (VKA) oral anticoagulation as a preventive 
strategy for most patients with AF, unless clearly identifiable to be at very-low-risk 2, 3. The recent 
availability of non-VKA oral anticoagulants (NOACs) is likely to increase the number of AF patients treated 
with these drugs for stroke prevention in the future. In some such patients atrial appendage occlusion devices 
are now also a viable alternative 3. 
All the pivotal trials comparing VKAs with the NOACs in AF have enrolled patients with so-called “non-
valvular” AF and excluded patients at particularly high risk of thromboembolism, such as those with AF 
accompanying mitral stenosis or patients with mechanical prosthetic valves 4-7. The reasons for not recruiting 
these patients in trials testing NOACs also included the possibility that the pathogenesis of 
thromboembolism may be substantially different from other types of AF. The distinction between “valvular” 
AF and “non-valvular” AF however still remains uncertain, with variable definitions adopted in the NOAC 
trials. This has led to therapeutic confusion, well illustrated by a recent web-based survey among over 500 
Italian physicians mainly involved in the prescription of anticoagulants to AF patients. Here only 57.1% of 
the cardiologists and 67.9% of the internists agreed that the existing definitions of non-valvular AF (e.g. 
from guidelines) were sufficiently clear 8.  
Because of this, we recently reviewed the literature related to the thromboembolic risk in AF in the presence 
of the various types of “valvular” heart diseases; definitions of the term in different trials with NOACs; and 
the use of the term in current and recent guidelines 9. Specifically, we addressed the risk of 
thromboembolism in AF with or without various forms of valvular heart disease; and the qualitative type of 
thrombus forming in such conditions, as both have implications for treatment 9. Conclusions of this analysis 
were that some forms of “valvular” heart disease accompanied by AF are an area where further 
investigation for the use of NOACs is warranted. This seems to be the case for AF accompanying 
mitral stenosis. 
 
Thromboembolic risk in mitral stenosis, with or without atrial fibrillation 
 
In the pre-surgery and pre-anticoagulant therapy era mitral stenosis was estimated to be responsible of 25% 
of all deaths from systemic embolism 10-12. Up to 80% of patients with mitral stenosis and systemic embolism 
show AF on the ECG. One third of embolic events occur within 1 month of the onset of AF, and two thirds 
occur within 1 year 13. 
Correlation between the occurrence of embolism and mitral orifice dimensions or even the presence or 
absence of heart failure symptoms is not strict 12, 14, 15, and embolism can be the first manifestation of mitral 
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stenosis 11, or it can occur in patients with mild mitral stenosis, even before the development of dyspnea 10, 11, 
13. It is also controversial whether patients with mitral stenosis but without AF or a previous embolic event 
are at higher risk for embolic events. This has resulted in low-grade recommendations for oral anticoagulants 
in moderate-to-severe mitral stenosis even in the absence of AF in recent guidelines 16-18. 
At the other extreme, patients with mitral stenosis and AF who have experienced an embolic event have 
recurrences at a rate of 15 to 40 events per 100 patient-months 14, 19-22, which is the highest rate of 
thromboembolism ever reported in AF.  
 
Thrombi in mitral stenosis, even in the absence of AF, appear to have a much more frequent location out of 
the left atrial appendage, and being much more often “giant”, even in recent literature 23-31. Attempts have 
been made in finding predictors of its formation outside of or in addition to the classical risk factors 32-36, but 
with uncertain results. 
 
The conclusion of this analysis is that AF with mitral stenosis, essentially on a rheumatic basis, is the 
form of AF with native valves with the highest risk of thromboembolism, probably related to the low-
flow patterns occurring in the left atrium in such a condition, and with a frequent location of the 
thrombus outside of the left atrial appendage. In moderate and severe mitral stenosis thrombi may 
also occur in the absence of AF. The pathogenesis of thrombosis in such conditions is at the highest 
extreme of the spectrum of the low-flow patterns generally occurring in other forms of AF due to the 
lack of coordinated left atrial contraction, in this specific case exacerbated by the obstruction to LA 
emptying due to the presence of a stenotic mitral valve orifice. Such patients have never been 
randomized between alternative treatments, but there are also no speficic reasons, at sharp variance 
from intra-cardiac thrombi occurring, with or without AF, in the presence of mechanical heart valves, 
to hypothesize a differential response to various anticoagulants. 
 
 
THE MAGNITUDE OF THE PROBLEM 
 
Rheumatic fever is still the most common cause of acquired heart disease in children and young adults 
worldwide. Although the incidence of rheumatic fever has declined sharply in most developed areas of the 
world, the disease remains a major problem in many developing countries. In addition, there are fluctuations 
in the incidence of the disease over time, the reasons for which remain only partially understood. In many 
developing countries the incidence of acute rheumatic fever approaches or exceeds 100 per 100,000 37. As to 
rheumatic heart disease, of which mitral stenosis is a hallmark, the prevalence has been estimated at 0.6 per 
1000 in the United States, but up to 21.0 per 1000 in Asia, 15.0 per 1000 in Africa, and 17.0 per 1000 in 
South America 37. With an anticipated and conservative incidence of thromboembolism of at least 2 episodes 
per 100 patients/year in the overall population of patients with mitral stenosis (of any severity), with or 
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without AF, one can calculate that countries such as India, Pakistan, Egypt and other North African 
countries, Brazil and several Arab countries, accounting for at least 2 billion people worldwide, suffer an 
incidence of thromboembolic stroke due to this disease at least around 4.000.000 (4 million) per year. 
Experience with the use of vitamin K antagonists (VKAs) in conditions where such treatments are available 
shows that this is a largely preventable burden. 
 
 
PROBLEMS WITH THE USE OF VITAMIN K ANTAGONISTS IN AREAS OF THE WORLD 
WITH HIGH PREVALENCE OF MITRAL STENOSIS 
 
There are no randomized trials examining the efficacy of anticoagulation (essentially VKAs) in preventing 
embolic events specifically in patients with mitral stenosis. Current recommendations are only based on 
retrospective studies showing a 4- to 15-fold decrease in the incidence of embolic events with 
anticoagulation in these patients 14, 20. Although with a high grade (Class I) because of the wide differential 
between treatment and no treatment, such recommendations are all level of evidence B in the case of mitral 
stenosis plus AF 17 (Class of recommendation and level of evidence not graded in the latest ESC Guidelines 
18).  
As indicated above, in recent guidelines there are also low-grade recommendations for oral anticoagulants in 
moderate-to-severe mitral stenosis even in the absence of AF 16-18. Specifically, current recommendations are 
Class IIb in the absence of AF [according to the presence of echocardiographic criteria of an enlarged left 
atrium and/or spontaneous echo-contrast (level of evidence B or C, respectively)] in the latest ACC/AHA 
Guidelines 17; recommendation class IIa, level of evidence C in the latest ESC Guidelines 18. 
The potential of VKAs in reducing the thromboembolic burden in mitral stenosis is however considerably 
hampered by the inability of achieving good quality of anticoagulation. In the setting of the Atrial 
Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)-W trial, 
comparing the efficacy of warfarin with the combination of aspirin plus clopidogrel in non-valvular AF, a 
post-hoc analysis evaluated times in therapeutic range (TTRs) of patients on VKAs. Here TTRs for patients 
under warfarin were used to calculate the mean TTR for each of 526 centers and 15 countries participating in 
the trial 38. Proportional-hazards analysis, with and without adjustment for baseline variables, was performed, 
with patients stratified by TTR quartile and country. A wide variation in TTRs was found between centers, 
with mean TTRs for centers in the 4 quartiles of 44%, 60%, 69%, and 78%. For patients at centers with TTR 
above the study median warfarin had a marked benefit, reducing vascular events by >2-fold (relative risk, 
2.14; 95% confidence interval, 1.61 to 2.85; P<0.0001). However, for patients at centers below the median 
TTR (65%) no treatment benefit was demonstrated, as measured by relative risk for vascular events of 
clopidogrel plus aspirin versus warfarin (relative risk, 0.93; 95% confidence interval, 0.70 to 1.24; P=0.61). 
Mean TTR also varied between countries from 46% to 78%, and relative risk (clopidogrel plus aspirin versus 
warfarin) varied from 0.6 to 3.6 (a 5-fold difference!). A population-average model predicted that TTR of 
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58% would be needed to be confident that patients would benefit from being on warfarin. Below this level 
there appears to be little benefit of warfarin over antiplatelet therapy 38. Below this TTR level, among the 15 
countries participating in ACTIVE-W, were countries such as South Africa (46.3%) Brazil (47.1%), Russia 
(53.4%) and Poland (55.3%). 
Similarly, an analysis of the RE-LY trial was carried out to assess efficacy and safety of dabigatran 
compared with warfarin for stroke prevention in AF at different levels of international normalized ratio 
(INR) control, assessed as each centre’s mean TTR (cTTR) in the warfarin population 39. The authors found 
that for all vascular events, non-hemorrhagic events, and death, advantages of dabigatran were greater at 
sites with poor INR control than at those with good INR control (albeit the interaction between quality of 
INR control and such outcomes was not formally statistically significant), overall pointing to the plausible 
hypothesis that local standards of care affect the relative benefits with the use of new treatment alternatives. 
From this analysis, countries with cTTR below the level of 58% (the threshold conservatively derived from 
the previous analysis 38), included Taiwan (44%), Mexico (47%), Peru (48%), Romania (49%), India (49%), 
Colombia (53%), Russia (53%), Brazil (54%), China (55%), Korea (55%), Greece (56%), Thailand (56%), 
Malaysia (56%), and Poland (57%) 39 (Figure 1).  
 
There is a wide overlap of poor quality of anticoagulation, as obtained from center-derived information and 
taken as an approximation of the country quality of anticoagulation, and the distribution of rheumatic heart 
disease and mitral stenosis in the world. Recently published data from the Global Rheumatic Heart Disease 
Registry (the REMEDY study) 40 show that oral anticoagulants (VKAs) were prescribed in 69.5% of patients 
with rheumatic heart disease and an indication for anticoagulation. Prescription was relatively high (91.6%) 
in patients with a mechanical valve, intermediate (68.6%) of patients with AF, and very low (20.3%) in those 
with mitral stenosis in sinus rhythm with either dilated left atrium or left atrial thrombus (high-risk mitral 
stenosis in sinus rhythm). Independent of prescriptions, however, of the patients on OACs for the recognized 
indications, 12.2% had had no INR monitoring, whereas 34.1% had only one to three INR tests in the 6 
months preceding enrollment in the registry. The INR at enrolment was subtherapeutic in 32.7%, therapeutic 
in 28.3%, and above the therapeutic range in 17.7%, with no INR testing on the remainder of 21.4%. Sixty 
percent of participants were unaware of the therapeutic range of INR 40. Estimates of anticoagulation quality 
are likely even over-optimistic, as derived from centers involved in clinical trials, with likely high 
motivation, probably overestimating the average anticoagulation quality in such countries. 
This information reliably tells us that in vast areas of the world where mitral stenosis is an important 
cause of stroke and systemic embolism, treatment with VKAs, with the well-known barriers to its 
optimization, is not a trustable and reliable treatment for stroke prevention. Alternative treatments, 
such as aspirin, possibly being given in such countries, are likely to be here reasonable alternative to 
badly controlled VKAs and remain a possible standard of therapy, despite their well-known inferiority 
compared with well-controlled VKA therapy 41. 
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THE PROPOSAL 
 
On the basis of these considerations, we believe it would be highly desirable to test the hypothesis of a 
superiority of any of the NOACs so far tested in AF in the setting of moderate/severe mitral stenosis, 
with or without concomitant AF, compared with “standard therapy”, consisting of the local treatment 
protocols, with either aspirin, or other antiplatelet agents—as single agent or in combination—or 
locally used VKAs. 
 
Key elements for this trial would be: 
1. An open-label design, increasing feasibility 
2. A comparison with the standards of care for thromboembolic prophylaxis, which may consist of 
antiplatelet agents (aspirin in most cases); or VKAs, but in which case the quality of INR control is to be 
expected as being poor 
3. A superiority design, which we consider rational on the basis of the considerations highlighted above 
4. To be conducted in countries, such as Mexico, Brazil, Egypt, South Africa, India, China, etc., where 
centers exist recruiting large numbers of patients with rheumatic heart disease, and where a possibility 
exists of patient follow-up 
5. Ideally with one of the NOACs available for once-daily use, considering the importance of practical 
aspects of long-term treatments in countries where difficulties in ensuring patients’ education to the 
importance of therapeutic adherence are higher than in developed countries 
6. Ideally with the same dosages of the NOACs used in pivotal trials in AF. 
 
While most of the above points are self-explicatory, the issue of the choice of the appropriate NOAC dosing 
requires some further reasoning and explanation.  
Besides the obvious advantage of the widest documentation of efficacy and safety, the following elements of 
knowledge argue for keeping the same “standard” NOAC dosing schemes already adopted and tested in the 
large 4 pivotal AF trials against warfarin in “non-valvular” AF 4-7: 
(a) despite the clearly higher thromboembolic risk of mitral stenosis compared with classical “non-
valvular” AF, there has never been a clear demonstration that a higher intensity of 
anticoagulation with VKAs is here warranted. Indeed, current guidelines 2, 3, 42, 43 and standard 
practice continue to recommend the same 2.0-3.0 INR for atrial fibrillation accompanying mitral 
stenosis, similarly to other types of AF; 
(b) for anticoagulation in atherothrombotic prophylaxis, such as post-myocardial infarction, the 
higher anticoagulation intensity (3.0-4.5 or similar) previously recommended and used in some 
trials 44-47 has never itself been demonstrated to be more effective (or more advantageous), than 
the standard 2.0-3.0 intensity 48; 
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(c) wherever a higher intensity VKA therapy is used, specifically in some settings of mechanical 
valve antithrombotic prophylaxis (e.g., with an unfavorable – tricuspid, mitral or pulmonary – 
mechanical valve position, in the presence of a medium- or high-thrombogenicity mechanical 
valve, or in the presence of comorbidities), its rationale is relatively weak 18, 49, and indeed not 
adopted in the ACC/AHA Guidelines 50; 
(d) in conditions of mechanical heart valves, the attempts of using one NOAC (dabigatran etexilate) 
in the RE-ALIGN study 51 at dosages (220 mg B.I.D.) higher than those used in “non-valvular” 
AF in the RE-LY trial 4 has certainly resulted in much and prohibitively higher rates of bleeding, 
without any evidence of increased efficacy 51. 
Therefore, on the background of a “standard” anticoagulation intensity used in mitral stenosis for 
VKAs, and of the considerable bleeding risk entailed by higher-than-standard NOAC dosing, we 
would strongly advise to use, in an advocated trial in mitral stenosis, the same NOAC dosages used in 
the pivotal “non-valvular” AF trials. 
 
STATISTICAL CONSIDERATIONS AND CALCULATION OF SAMPLE SIZE 
 
In the Apixaban VErsus acetylsalicylic acid to Reduce the Risk Of Embolic Stroke (AVERROES) trial 52, 
which was a comparison of the factor Xa inhibitor apixaban with aspirin in patients with AF at a raised risk 
of stroke, but who were considered not suitable candidates or were unwilling to receive VKA therapy, 
apixaban proved significantly superior to aspirin for preventing stroke and systemic embolism (hazard ratio 
with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P<0.001), therefore with a 55% reduction of 
the primary endpoint.  
 Considering that some of the patients recruitable in this study may also receive VKA therapy, which 
is likely to be not well controlled anyhow for the considerations highlighted above, we hypothesize a 
more conservative hazard ratio of the NOAC vs the local standard-of-care of 0.70 (30% relative risk 
reduction in the primary endpoint of stroke and systemic embolism). Calculations of sample size will 
allow variations of this estimate up to 0.80. 
 We hypothesize to recruit patients with moderate or severe mitral stenosis [standard echo criteria of a 
mitral valve area <1.5 cm2 (measured by planimetry and the pressure-half-time method, which are 
complementary)], according to current guidelines 18, 50. In such patients the rate of stroke is to be 
considered in the order of 5-10 per 100 patients/year, since including also patients without AF. 
 We hypothesize recruiting in at least two countries (e.g., Mexico and South-East China), where we 
have preliminarily inquired the feasibility and willingness of local doctors to participate. 
 
Sample size calculation 
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Assuming an alpha error of 0.05; a beta error of 0.20 (statistical power of 0.80); a dropout/withdrawal rate of 
5% per year; a NOAC/standard of care groups ratio of 1:1; using a log-rank test, the overall sample sizes that 
would be required with various combinations of stroke rates (from 5% to 10%), NOAC efficacy over the 
standard of care (hazard ratios 0.70; 0.75; 0.80); and study duration (1 to 3 years), are reported in Table 1. 
The sample size of each group corresponds to the overall sample size (in Table 1) divided by two. 
 
CONCLUSIONS 
 
A randomized trial of one of the NOACs against the best-of-treatment available in regions of the world 
in which rheumatic heart disease is still highly prevalent, aiming at showing the superiority of the 
NOAC used against current standard treatment, appears feasible and highly desirable. 
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FIGURE LEGEND 
 
Figure 1: Country distribution of the mean time in therapeutic range (TTR) in the RE-LY trial. Source: Ref. 
39, redrawn. 
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 Study Duration: 1 year 
Stroke rate x100 py 5 6 7 8 9 10 
HR: 0.70 2940 2520 2100 1890 1680 1470 
HR: 0.75 3990 3570 3150 2730 2310 2100 
HR: 0.80 6930 5742 4892 4254 3734 3318 
       
 Study Duration: 2 years 
Stroke rate x100 py 5 6 7 8 9 10 
HR: 0.70 1580 1390 1162 1044 926 812 
HR: 0.75 2152 1938 1726 1482 1270 1164 
HR: 0.80 3732 3110 2668 2334 2050 1822 
       
 Study Duration: 3 years 
Stroke rate x100 py 5 6 7 8 9 10 
HR: 0.70 1144 990 848 744 684 594 
HR: 0.75 1554 1372 1242 1086 940 846 
HR: 0.80 2652 2210 1894 1684 1498 1346 
 
Table 1. Overall sample size computation (py = person-years). 
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